No Deal: Omnibus Spending Bill Moves Without Part D Discount Relief
Biopharma lobbying to include provision to reduce the 70% discount on brands in the budget bill runs out of time, leaving industry evaluating other possible legislative vehicles.
You may also be interested in...
Biopharma will continue to seek ways to pass legislation reducing the 70% discount in Medicare Part D coverage gap but it looks like industry's next chance will be after the November elections.
Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.
PhRMA President Ubl discusses drug pricing advocacy priorities in Medicare Part D during media briefing.